Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 11/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573839 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18685100 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611990 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189194 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12285684 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19620437 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189312 | 0.93 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189322 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189269 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19227110 | 0.92 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | OMNISINO HEALTH (TIANJIN) MEDICAL TECHNOLOGY CO. LTD (CN) | 2023-11-23 | — | — | US | claimed |
| US-20230346817-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RESEARCH CO. LTD. (CN) | 2023-11-02 | — | — | US | claimed |
| EP-4206212-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| EP-4197543-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. (CN) | 2023-06-21 | — | — | EP | claimed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | claimed |
| WO-2022036506-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | 天津睿创康泰生物技术有限公司 | 2022-02-24 | — | — | WO | claimed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20250340520-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025202212-A1 | METHODS FOR DIAGNOSING ADVANCED LIVER FIBROSIS OR LIVER CIRRHOSIS | GENFIT (FR) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025202134-A1 | METHODS FOR DIAGNOSING ADVANCED LIVER FIBROSIS OR LIVER CIRRHOSIS | GENFIT (FR) | 2025-10-02 | — | — | WO | disclosed |
| WO-2022062401-A1 | PREPARATION METHOD FOR TIANAGLIFLOZIN | 广州市力鑫药业有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022036506-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | 天津睿创康泰生物技术有限公司 | 2022-02-24 | — | — | WO | disclosed |
| WO-2020155098-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 天津药物研究院有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-2069374-B1 | CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013090550-A1 | NOVEL GLYCOSIDE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-06-20 | — | — | WO | disclosed |
| EP-2457918-A2 | Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | Bristol-Myers Squibb Company (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2008002824-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1643/4885 |
| US-20230346817-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | SLC5A2, SLC5A1, AGTR2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 114/4885 |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | AGTR2, AGTR1, AGT | SLC5A2 62/4885SLC5A1 84/4885ADRA2A 26/4885 |
| US-20250340520-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | AGTR1, AGTR2, AGT | SLC5A2 45/4885SLC5A1 63/4885ADRA2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.